M K Söderlin1, P Geborek. 1. Spenshult Rheumatology Hospital, Oskarström, Sweden. soderlin@spenshult.se
Abstract
OBJECTIVE: To study prescription patterns of biological treatment in rheumatoid arthritis (RA) patients in southern Sweden, a region with no formal or economic restrictions for the use of biological treatment in rheumatological diseases. Specifically, we studied conformity with the national Swedish guidelines for biologics in RA. METHODS: Rheumatologists in southern Sweden contribute to a voluntary register on the use of biologics in treating arthritis patients (the South Swedish Arthritis Treatment Group (SSATG)). This register covers .90% of all the prescriptions of biologics for arthritis patients in the region. The treatment of 1839 patients (2704 treatment occasions) was recorded in the SSATG register during 1999-2006. Baseline characteristics were analysed. RESULTS: Baseline Health Assessment Questionnaire(HAQ) scores and Disease Activity Scores (DASs)decreased significantly between 1999 and 2006, but disease activity remained high in RA patients. RA patients were treated with biologics earlier, but only 16% of the patients received biologics within 2 years of disease onset in 2006. The percentage of RA patients who were prescribed biologics after only one previous non-biological DMARD (disease-modifying anti-inflammatory rheumatic drug) was 27% in 2006. Thirty-five per cent of all RA patients changed from one biological treatment to another. CONCLUSIONS: Baseline DASs in RA patients remained high at the start of biological treatment. The national Swedish guidelines for the prescription of biologics in RA were followed. More patients with early RA were treated with biologics. The proportion of RA patients changing from one biological drug to another increased.
OBJECTIVE: To study prescription patterns of biological treatment in rheumatoid arthritis (RA) patients in southern Sweden, a region with no formal or economic restrictions for the use of biological treatment in rheumatological diseases. Specifically, we studied conformity with the national Swedish guidelines for biologics in RA. METHODS: Rheumatologists in southern Sweden contribute to a voluntary register on the use of biologics in treating arthritispatients (the South Swedish Arthritis Treatment Group (SSATG)). This register covers .90% of all the prescriptions of biologics for arthritispatients in the region. The treatment of 1839 patients (2704 treatment occasions) was recorded in the SSATG register during 1999-2006. Baseline characteristics were analysed. RESULTS: Baseline Health Assessment Questionnaire(HAQ) scores and Disease Activity Scores (DASs)decreased significantly between 1999 and 2006, but disease activity remained high in RApatients. RApatients were treated with biologics earlier, but only 16% of the patients received biologics within 2 years of disease onset in 2006. The percentage of RApatients who were prescribed biologics after only one previous non-biological DMARD (disease-modifying anti-inflammatory rheumatic drug) was 27% in 2006. Thirty-five per cent of all RApatients changed from one biological treatment to another. CONCLUSIONS: Baseline DASs in RApatients remained high at the start of biological treatment. The national Swedish guidelines for the prescription of biologics in RA were followed. More patients with early RA were treated with biologics. The proportion of RApatients changing from one biological drug to another increased.
Authors: Ingrid Lekander; Fredrik Borgström; Jörgen Lysholm; Ronald F van Vollenhoven; Staffan Lindblad; Pierre Geborek; Gisela Kobelt Journal: Eur J Health Econ Date: 2012-09-19
Authors: Hilbert S de Vries; Martijn G H van Oijen; Rieke J B Driessen; Elke M G J de Jong; Marjonne C W Creemers; Wietske Kievit; Dirk J de Jong Journal: Br J Clin Pharmacol Date: 2011-01 Impact factor: 4.335
Authors: Maria de la Vega; Hellen M da Silveira de Carvalho; Lucio Ventura Ríos; Maria V Goycochea Robles; Gustavo C Casado Journal: Rheumatol Int Date: 2012-12-23 Impact factor: 2.631
Authors: Regina Rendas-Baum; Gene V Wallenstein; Tamas Koncz; Mark Kosinski; Min Yang; John Bradley; Samuel H Zwillich Journal: Arthritis Res Ther Date: 2011-02-16 Impact factor: 5.156
Authors: Johannes Cornelis Schrama; Anne M Fenstad; Håvard Dale; Leif Havelin; Geir Hallan; Søren Overgaard; Alma B Pedersen; Johan Kärrholm; Göran Garellick; Pekka Pulkkinen; Antti Eskelinen; Keijo Mäkelä; Lars B Engesæter; Bjørg-Tilde Fevang Journal: Acta Orthop Date: 2015-03-17 Impact factor: 3.717
Authors: M Neovius; E V Arkema; H Olsson; J K Eriksson; L E Kristensen; J F Simard; J Askling Journal: Ann Rheum Dis Date: 2013-11-27 Impact factor: 19.103
Authors: Karin Bengtsson; Lennart T H Jacobsson; Barbro Rydberg; Göran Kvist; Tomas Torstenson; Mats Dehlin; Elisabet Hilme; Anna Lindhé; Susanna Maria Wallerstedt; Helena Forsblad-d'Elia Journal: BMC Musculoskelet Disord Date: 2016-12-12 Impact factor: 2.362